CAM
ACHN

Cormorant Asset Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Cormorant Asset Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,006,128
Closed -$8.15M – 89
2016
Q3 		$8.15M Hold
1,006,128
– – 0.9% 36
2016
Q2 		$7.85M Buy
1,006,128
+506,128
+101% +$4.34M 1.11% 33
2016
Q1 		$3.86M Hold
500,000
– – 0.58% 45
2015
Q4 		$5.39M Buy
+500,000
New +$4.55M 0.65% 45

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Cormorant Asset Management's ACHN Position: Q4 2016 in Review

Cormorant Asset Management sold out of Achillion Pharmaceuticals (ACHN) in Q4 2016, closing a stake of 1,006,128 shares — an estimated $8.15M sold.

Cormorant Asset Management first reported a position in ACHN in Q4 2015 and held it in 4 quarters. The position peaked at $8.15M in Q3 2016. 140 funds tracked by Wall St. Rank hold ACHN as of Q4 2016.

  • Cormorant Asset Management reported no remaining Achillion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Cormorant Asset Management sold 1,006,128 Achillion Pharmaceuticals shares in Q4 2016, an estimated $8.15M.
  • Cormorant Asset Management first reported a position in Achillion Pharmaceuticals in Q4 2015 and held it in 4 quarters.
  • Cormorant Asset Management's Achillion Pharmaceuticals position peaked at $8.15M in Q3 2016.
  • 140 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2016.

Based on Cormorant Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.